Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate

Liver International

Volumn 32, Issue 6, 2012, Pages 1008-1017

  Kim, Youngchul ^a,b   Fiel, Maria I ^a   Albanis, Efsevia ^a   Chou, Hsin I ^a   Zhang, Weijia ^a   Khitrov, Gregory ^a   Friedman, Scott L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Kyung Hee University   (South Korea)

Author keywords

Hepatic regeneration; LX 2 cells; Microarray; PGDF receptor; Tyrosine kinase

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBRINOLYTIC AGENT; COLLAGEN TYPE 1; COMPLEMENTARY DNA; GELATINASE A; IMATINIB; INTERLEUKIN 6; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SUPEROXIDE; THIOACETAMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA MICROARRAY; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; MALE; MITOCHONDRION; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RAT; STELLATE CELL; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; CELL LINE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; HEPATIC STELLATE CELLS; HUMANS; INTERLEUKIN-6; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RNA, MESSENGER; THIOACETAMIDE; TIME FACTORS; UP-REGULATION;

EID: 84861970535     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02806.x     Document Type: Article

References (52)

1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-69.
2. Parola M, Pinzani M. Hepatic wound repair. Fibrogenesis Tissue Repair 2009; 2: 4.
3. Ankoma-Sey V, Matli M, Chang KB, et al. Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing. Oncogene 1998; 17: 115-21.
4. Yoshiji H, Kuriyama S, Yoshii J, et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003; 52: 1347-54.
5. Olaso E, Salado C, Egilegor E, et al. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 2003; 37: 674-85.
6. Wong L, Yamasaki G, Johnson RJ, Friedman SL. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994; 94: 1563-9.
7. Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front Biosci 2002; 7: d1720-6.
8. Breitkopf K, Roeyen C, Sawitza I, et al. Expression patterns of PDGF-A, -B, -C and -D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cells (HSC). Cytokine 2005; 31: 349-57.
9. Lafdil F, Chobert MN, Couchie D, et al. Induction of Gas6 protein in CCl4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells. Hepatology 2006; 44: 228-39.
10. Olaso E, Labrador JP, Wang L, et al. Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem 2002; 277: 3606-13.
11. Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2010; 9: 956-70.
12. Dai Y. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature. Expert Opin Ther Pat 2010; 20: 885-97.
13. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10: 470-81.
14. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002; 8: S14-8.
15. Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005; 5: 171-93.
16. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 2010; 152: 159-66.
17. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008; 5: e19.
18. Leipner C, Grun K, Muller A, et al. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis. Cardiovasc Res 2008; 79: 118-26.
19. Yoshiji H, Kuriyama S, Noguchi R, et al. Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. Int J Mol Med 2006; 17: 899-904.
20. Yoshiji H, Noguchi R, Kuriyama S, et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288: G907-13.
21. Neef M, Ledermann M, Saegesser H, et al. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol 2006; 44: 167-75.
22. Roskams T. Relationships among stellate cell activation, progenitor cells, and hepatic regeneration. Clin Liver Dis 2008; 12: 853-60, ix.
23. Schirmacher P, Geerts A, Pietrangelo A, Dienes HP, Rogler CE. Hepatocyte growth factor/hepatopoietin A is expressed in fat-storing cells from rat liver but not myofibroblast-like cells derived from fat-storing cells. Hepatology 1992; 15: 5-11.
24. Maher JJ. Cell-specific expression of hepatocyte growth factor in liver. Upregulation in sinusoidal endothelial cells after carbon tetrachloride. J Clin Invest 1993; 91: 2244-52.
25. Kendall TJ, Hennedige S, Aucott RL, et al. p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis. Hepatology 2009; 49: 901-10.
26. Suzuki K, Tanaka M, Watanabe N, et al. p75 Neurotrophin receptor is a marker for precursors of stellate cells and portal fibroblasts in mouse fetal liver. Gastroenterology 2008; 135: 270-81 e273.
27. Asai K, Tamakawa S, Yamamoto M, et al. Activated hepatic stellate cells overexpress p75NTR after partial hepatectomy and undergo apoptosis on nerve growth factor stimulation. Liver Int 2006; 26: 595-603.
28. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274: 1379-83.
29. Bansal MB, Kovalovich K, Gupta R, et al. Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J Hepatol 2005; 42: 548-56.
30. Xu L, Hui AY, Albanis E, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005; 54: 142-51.
31. Friedman SL, Rockey DC, McGuire RF, et al. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology 1992; 15: 234-43.
32. Friedman SL, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest 1989; 84: 1780-5.
33. Lechuga CG, Hernandez-Nazara ZH, Hernandez E, et al. PI3K is involved in PDGF-beta receptor upregulation post-PDGF-BB treatment in mouse HSC. Am J Physiol Gastrointest Liver Physiol 2006; 291: G1051-61.
34. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
35. Irizarry RA, Bolstad BM, Collin F, et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: e15.
36. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-21.
37. Hwang RF, Yokoi K, Bucana CD, et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003; 9: 6534-44.
38. Trim JE, Samra SK, Arthur MJ, et al. Upstream tissue inhibitor of metalloproteinases-1 (TIMP-1) element-1, a novel and essential regulatory DNA motif in the human TIMP-1 gene promoter, directly interacts with a 30-kDa nuclear protein. J Biol Chem 2000; 275: 6657-63.
39. Novo E, Parola M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair 2008; 1: 5.
40. Moehring A, Wohlbold L, Aulitzky WE, van der Kuip H. Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death. Cell Death Differ 2005; 12: 627-36.
41. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-16.
42. Cataldi M, Gaudino A, Lariccia V, et al. Imatinib-mesylate blocks recombinant T-type calcium channels expressed in human embryonic kidney-293 cells by a protein tyrosine kinase-independent mechanism. J Pharmacol Exp Ther 2004; 309: 208-15.
43. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007; 213: 286-300.
44. Muller A, Machnik F, Zimmermann T, Schubert H. Thioacetamide-induced cirrhosis-like liver lesions in rats-usefulness and reliability of this animal model. Exp Pathol 1988; 34: 229-36.
45. Clouston AD, Powell EE, Walsh MJ, et al. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005; 41: 809-18.
46. Liu Y, Lui EL, Friedman SL, et al. PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling. Lab Invest 2009; 89: 209-21.
47. Liu Y, Wen XM, Lui EL, et al. Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258. Lab Invest 2009; 89: 1152-60.
48. Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Ann Hepatol 2009; 8: 283-91.
49. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117: 539-48.
50. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-4.
51. Skorta I, Oren M, Markwardt C, et al. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity. Cancer Res 2009; 69: 9337-45.
52. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A 1991; 88: 7605-9.